Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inupadenant new formulations in advanced solid tumors
NCT05117177Phase 1Completed
- Sponsor
- iTeos Therapeutics
- Start
- Jul 2021
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of inupadenant in solid tumor (3 arms), sponsored by iTeos Therapeutics. Primary endpoints: Incidence of Dose-Limiting Toxicities and Incidence and severity of Adverse Events. Started Jul 2021; status: completed.
02
Drugs
inupadenant
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05117177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05117177.